AVIEW

The AVIEW device is a medical imaging system designed to provide quantitative analysis of CT images for pulmonary and cardiovascular assessment. It employs image segmentation, density evaluation, and advanced algorithms to characterize lung nodules and calculate coronary artery calcium scores, thereby aiding in the diagnosis and risk stratification of these conditions.

The AVIEW device, developed by Coreline Soft Co., Ltd., has achieved substantial equivalence for its intended uses, enabling its market availability as a Class II Medical Image Management and Processing System. This regulatory determination by the FDA underscores its compliance with general controls and other applicable requirements, including those for manufacturing, labeling, and unique device identification, affirming its readiness for clinical application. AVIEW is designed to perform quantitative analysis of CT images from both thoracic and cardiac datasets, offering functionalities such as image segmentation for lung, lobe, airways, and cardiac structures, alongside density evaluation and comprehensive reporting. It supports the characterization of lung nodules through various measurements and classifications like Lung-RADS, and integrates capabilities for coronary artery calcification scoring using Agatston, volume, and mass calculations, primarily indicated for adult patients. The system also facilitates robust CT data management through both on-premises and cloud environments.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does AVIEW's quantitative analysis of lung nodules compare in accuracy and reliability to current gold-standard methods for early cancer detection?; What is the clinical impact of integrating AVIEW's coronary artery calcification scoring with existing cardiovascular risk assessment models?; Can AVIEW's cloud-based data management system ensure data security and interoperability with various hospital PACS systems effectively?; Are there specific clinical scenarios or patient populations where AVIEW's diagnostic capabilities offer significant advantages over traditional image review?; What is the required level of training for clinicians and technicians to accurately interpret and utilize AVIEW's output for patient management?